KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Assets (2017 - 2025)

Historic Non-Current Assets for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $11.9 million.

  • Aquestive Therapeutics' Non-Current Assets fell 1121.9% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year decrease of 1585.48%. This contributed to the annual value of $13.2 million for FY2024, which is 1974.23% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Non-Current Assets of $11.9 million as of Q3 2025, which was down 1121.9% from $12.0 million recorded in Q2 2025.
  • Aquestive Therapeutics' Non-Current Assets' 5-year high stood at $17.6 million during Q1 2023, with a 5-year trough of $11.9 million in Q3 2025.
  • Moreover, its 5-year median value for Non-Current Assets was $14.7 million (2021), whereas its average is $14.9 million.
  • In the last 5 years, Aquestive Therapeutics' Non-Current Assets skyrocketed by 3436.94% in 2023 and then tumbled by 2120.53% in 2024.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' Non-Current Assets stood at $14.7 million in 2021, then increased by 16.61% to $17.2 million in 2022, then dropped by 4.25% to $16.5 million in 2023, then fell by 19.74% to $13.2 million in 2024, then decreased by 9.98% to $11.9 million in 2025.
  • Its Non-Current Assets was $11.9 million in Q3 2025, compared to $12.0 million in Q2 2025 and $13.1 million in Q1 2025.